

Markus Pfirrmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6677374/publications.pdf>

Version: 2024-02-01

23
papers

2,515
citations

623734

14
h-index

794594

19
g-index

24
all docs

24
docs citations

24
times ranked

1730
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group. <i>Journal of the National Cancer Institute</i> , 1998, 90, 850-859.	6.3	728
2	Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. <i>Blood</i> , 2011, 118, 686-692.	1.4	413
3	Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon- α in Newly Diagnosed Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 1634-1642.	1.6	307
4	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. <i>Journal of Clinical Oncology</i> , 2014, 32, 415-423.	1.6	271
5	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. <i>Blood</i> , 2010, 115, 1880-1885.	1.4	198
6	Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. <i>Blood</i> , 2007, 109, 4686-4692.	1.4	141
7	Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. <i>Haematologica</i> , 2014, 99, 1441-1447.	3.5	97
8	Interferon- α Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure. <i>Blood</i> , 1999, 94, 3668-3677.	1.4	91
9	The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. <i>Leukemia</i> , 2019, 33, 1173-1183.	7.2	83
10	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2138-2149.	7.2	55
11	No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 843-850.	2.5	34
12	Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. <i>Annals of Hematology</i> , 2015, 94, 209-218.	1.8	22
13	Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. <i>Cancer</i> , 2017, 123, 2467-2471.	4.1	18
14	Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. <i>American Journal of Hematology</i> , 2019, 94, 1236-1243.	4.1	17
15	CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance. <i>Frontiers in Neurology</i> , 2021, 12, 654543.	2.4	13
16	Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study. <i>Molecular Metabolism</i> , 2018, 9, 168-175.	6.5	12
17	Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α -interferon: comments. <i>British Journal of Haematology</i> , 2001, 114, 241-241.	2.5	7
18	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1367-1381.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Clinical Trials in Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports, 2012, 7, 109-115.	2.3	3
20	Prognostic Scores for Patients with Chronic Myeloid Leukemia Under Particular Consideration of Disease-Specific Death. Hematologic Malignancies, 2016, , 111-128.	0.2	0
21	Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death. Hematologic Malignancies, 2021, , 119-143.	0.2	0
22	The European Leukemia Net CML Registry - Objectives, Achievements and First Results.. Blood, 2006, 108, 4781-4781.	1.4	0
23	Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).. Journal of Clinical Oncology, 2017, 35, 7049-7049.	1.6	0